Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-adapted de-escalation CCRT in HPV-positive oropharyngeal squamous cell carcinoma
ChiCTR2600128503Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cisplatin in oropharyngeal squamous cell carcinoma (OPSCC) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Progression-free survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
cisplatin
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on ChiCTR2600128503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128503.